真实世界中西医结合治疗中危冠状动脉病变的多中心研究
多中心前瞻性队列纳入1282例中危冠状动脉病变患者,比较中西医结合(ICWM)与单纯西医(WM)的疗效与安全性。ICWM组668例、WM组614例,中位随访1053天。调整后ICWM显著降低MACE(HR 0.53,95%CI 0.30-0.95)、MACCE(HR 0.53,95%CI 0.31-0.89)及复合终点(HR 0.64,95%CI 0.47-0.87),且不良反应无显著差异。
要点
- 中危冠脉病变患者接受≥12周/年中药治疗与心脑血管事件风险降低相关。
- 倾向评分匹配后ICWM对MACE、MACCE及复合终点仍优于单纯WM。
- 两组报告的不良反应无显著差异,安全性相当。
核心结论
- 真实世界实践中,ICWM较单纯WM显著减少中危冠状动脉病变患者的心脑血管事件,且未增加不良反应。
研究设计与样本
- 多中心前瞻性队列研究,纳入15家医院连续1282例患者(ICWM 668例,WM 614例)。
- ICWM定义为每年同时使用中药或中成药≥12周,随访中位1053天。
主要发现
- MACE发生52例、MACCE 63例、复合终点180例。
- 调整后ICWM降低MACE风险(HR 0.53,95%CI 0.30-0.95)、MACCE风险(HR 0.53,95%CI 0.31-0.89)及复合终点风险(HR 0.64,95%CI 0.47-0.87)。
- Fine-Gray分析证实累积发生率更低(p<0.05),所有敏感性分析结果一致。
- 1:1 PSM队列(n=932)中ICWM对MACE(HR 0.35)、MACCE(HR 0.41)及复合终点(HR 0.64)仍更优,log-rank p<0.05。
关键数值与推荐
- ICWM组与WM组报告的不良反应无显著差异。
临床怎么用
- 对中危冠状动脉病变患者,可考虑在WM基础上联合中药或中成药≥12周/年以降低心脑血管事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effectiveness and safety of integrated traditional Chinese and Western medicine (ICWM) with Western medicine (WM) alone in patients with intermediate coronary lesions. METHODS: In this multicenter prospective cohort, 1282 consecutive patients from 15 hospitals were enrolled (ICWM 668; WM 614). ICWM was defined as ≥ 12 weeks per year of concomitant Chinese herbal or proprietary preparations. Outcomes were assessed at 3, 6, and 12 months and again between May and November 2023 (median follow-up 1053 days). The primary endpoint was major adverse cardiovascular events (MACE). Secondary endpoints were major adverse cardiovascular and cerebrovascular events (MACCE) and a broader composite outcome. Hazard ratios (HRs) were estimated with Cox and Fine-Gray models; robustness was tested with sensitivity, propensity-score-matched (PSM) and subgroup analyses. RESULTS: MACE occurred in 52 patients, MACCE in 63, and the composite endpoint in 180. After adjustment, ICWM significantly reduced the risk of MACE (HR 0.53, 95 % CI 0.30-0.95), MACCE (HR 0.53, 95 % CI 0.31-0.89) and the composite endpoint (HR 0.64, 95 % CI 0.47-0.87). Fine-Gray analysis confirmed lower cumulative incidences (p < 0.05). Findings remained consistent in all sensitivity analyses. In the 1:1 PSM cohort (n = 932), ICWM remained superior for MACE (HR 0.35), MACCE (HR 0.41) and the composite outcome (HR 0.64); all log-rank p < 0.05. There was no significant difference in adverse reactions reported between the two groups. CONCLUSION: In real-world practice, ICWM is associated with markedly fewer cardiovascular and cerebrovascular events than WM alone, without increased adverse reactions.
引用
- Wang X, Wang T, Jia Y, et al. Real-world applications of integrated traditional Chinese and Western medicine in patients with intermediate coronary lesions: Insights from a multicenter observational cohort study. Phytomedicine. 2026. PMID: 41795296. doi:10.1016/j.phymed.2026.157994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。